Rituximab for anti-NMDAR encephalitis

Rituximab for anti-NMDAR encephalitis - Rituximab for anti-NMDAR encephalitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026293

Enrollment

Registered

2017-03-31

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anti-NMDAR encephalitis

Interventions

Rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: intractable patients with anti-NMDAR encephalitis

Exclusion criteria

Exclusion criteria: infant, pregnant woman

Design outcomes

Primary

Measure	Time frame
cerebrospinal fluid (anti-NMDAR antibodies titer) This item is evaluated before and after RTX administration (at 1, 3, 6months)	—

Secondary

Measure	Time frame
blood examination (CD20+ lymphocyte, anti-NMDAR antibodies titer) brain MRI EEG modified Rankin scale These items are evaluated before and after RTX administration (at 1, 3, 6, 9, and 12 months)	—

Countries

Japan

Contacts

Public ContactNaoko Matsui

Tokushima University Hospital Neurology

naoko@tokushima-u.ac.jp088-633-7207

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026